Special Issue "Biomarkers in Chronic Fatigue Syndrome (ME/CFS)"
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 11943
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a systemic disease that affects the central nervous system, the immune system, cell energy metabolism, the autonomic nervous system, etc. The main clinical sign is persistent chronic fatigue that is not relieved by rest and lasts for more than six months. Up to 75% of patients are completely unable to work and remain wheelchair-dependent, and at least 25% are permanently housebound or even bedbound. Accordingly, the socio-economic impact of the disease is huge. At present, no curative treatment options are available. Therefore, patients have practically no prospect of recovery or at least of returning to work. Etiological factors for ME/CFS include genetic predisposition, stress, trauma, exposure to toxins, the ratio of physical activity to rest, and a recent history of infectious disease. ME/CFS can affect individuals from all races, genders, age groups, and social statuses. The pathogenesis of ME/CFS is likely multi-factorial and various microbial and viral infections can serve as possible triggers for ME/CFS. However, to date, no single biomarker has been identified that can be generalized to the entire patient population. Considering the heterogeneity of ME/CFS, it is plausible that a specific set of biomarkers might enable us to define disease subtypes. Identification of biomarkers will allow for prognosis of the disease’s development and promote the development of a specific definition for diagnostics and a treatment plan. Hence, I encourage researchers from diverse backgrounds (clinics, systems medicine, genetics, molecular biology, epidemiology) to contribute original research and review articles on any aspect of biomarker identification, biomarker characterization, or translational approaches of clinical relevance to this Special Issue, which aims to bring ideas from different fields of science to one common platform that may stimulate further research and solve a modern day clinical mystery.
Dr. Bhupesh K. Prusty
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2100 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Small RNAs
- Mitochondrial dysfunction
- Host-pathogen interaction
- microbial pathogenesis